The Eurocine® L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination

Vaccine

Volumn 28, Issue 39, 2010, Pages 6491-6497

  Petersson, Pernilla ^a,b   Hedenskog, Mona ^a   Alves, Denise ^a   Brytting, Mia ^a   Schröder, Ulf ^b   Linde, Annika ^a,b   Lundkvist, Åke ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Challenge studies; Influenza; Intranasal vaccination; Lipid adjuvants; Mice; Quantitative PCR

Indexed keywords

EUROCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; L3A; L3B; L3B SO; SUBUNIT INFLUENZA ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPID; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTOPSY; CONTROLLED STUDY; COPY NUMBER VARIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION; IMMUNIZATION; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE CULTURE; VIRUS IMMUNITY; ANIMAL; BLOOD; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INTRANASAL DRUG ADMINISTRATION; LUNG; ORTHOMYXOVIRUS INFECTION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; LIPIDS; LUNG; MICE; ORTHOMYXOVIRIDAE INFECTIONS; RNA, VIRAL; VACCINES, SUBUNIT;

EID: 77956402347     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.001     Document Type: Article

References (30)

1. Kieny M.P., Costa A., Hombach J., Carrasco P., Pervikov Y., Salisbury D., et al. A global pandemic influenza vaccine action plan. Vaccine 2006, 24(40-41):6367-6370.
2. Takada A., Matsushita S., Ninomiya A., Kawaoka Y., Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003, 21(23):3212-3218.
3. Ichinohe T., Tamura S., Kawaguchi A., Ninomiya A., Imai M., Itamura S., et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 2007, 196(9):1313-1320.
4. Perrone L.A., Ahmad A., Veguilla V., Lu X., Smith G., Katz J.M., et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009, 83(11):5726-5734.
5. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25(30):5467-5484.
6. Kemble G., Greenberg H. Novel generations of influenza vaccines. Vaccine 2003, 21(16):1789-1795.
7. Hagenaars N., Mastrobattista E., Glansbeek H., Heldens J., van den Bosch H., Schijns V., et al. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 2008, 26(51):6555-6563.
8. Hinkula J., Devito C., Zuber B., Benthin R., Ferreira D., Wahren B., et al. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine 2006, 24(21):4494-4497.
9. Schroder U., Svenson S.B. Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Vaccine 1999, 17(15-16):2096-2103.
10. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 2009, 4(9):e6999.
11. Stohr K. The global agenda on influenza surveillance and control. Vaccine 2003, 21(16):1744-1748.
12. Johansen K., Schroder U., Svensson L. Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants. Vaccine 2003, 21(5-6):368-375.
13. Rimmelzwaan G.F., Kreijtz J.H., Bodewes R., Fouchier R.A., Osterhaus A.D. Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 2009, 27(45):6363-6365.
14. Enbom M., Strand A., Falk K.I., Linde A. Detection of Epstein-Barr virus, but not human herpesvirus 8, DNA in cervical secretions from Swedish women by real-time polymerase chain reaction. Sex Transm Dis 2001, 28(5):300-306.
15. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(9):896-903.
16. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000, 165(9):4778-4782.
17. Myc A., Kukowska-Latallo J.F., Bielinska A.U., Cao P., Myc P.P., Janczak K., et al. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 2003, 21(25-26):3801-3814.
18. Bielinska A.U., Janczak K.W., Landers J.J., Makidon P., Sower L.E., Peterson J.W., et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 2007, 75(8):4020-4029.
19. Joseph A., Itskovitz-Cooper N., Samira S., Flasterstein O., Eliyahu H., Simberg D., et al. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 2006, 24(18):3990-4006.
20. Ninomiya A., Ogasawara K., Kajino K., Takada A., Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 2002, 20(25-26):3123-3129.
21. Asahi Y., Yoshikawa T., Watanabe I., Iwasaki T., Hasegawa H., Sato Y., et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 2002, 168(6):2930-2938.
22. Brandtzaeg P., Pabst R. Let's go mucosal: communication on slippery ground. Trends Immunol 2004, 25(11):570-577.
23. Bakke H., Samdal H.H., Holst J., Oftung F., Haugen I.L., Kristoffersen A.C., et al. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scand J Immunol 2006, 63(3):223-231.
24. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001, 51(1-3):81-96.
25. Bacon A., Makin J., Sizer P.J., Jabbal-Gill I., Hinchcliffe M., Illum L., et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 2000, 68(10):5764-5770.
26. Plante M., Jones T., Allard F., Torossian K., Gauthier J., St-Felix N., et al. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine 2001, 20(1-2):218-225.
27. Barchfeld G.L., Hessler A.L., Chen M., Pizza M., Rappuoli R., Van Nest G.A. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine 1999, 17(7-8):695-704.
28. Boyce T.G., Hsu H.H., Sannella E.C., Coleman-Dockery S.D., Baylis E., Zhu Y., et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 2000, 19(2-3):217-226.
29. Brandtzaeg P. Role of mucosal immunity in influenza. Dev Biol 2003, 115:39-48.
30. Stephenson I., Nicholson K.G., Wood J.M., Zambon M.C., Katz J.M. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004, 4(8):499-509.